IGES Life Science at the health economics conference ISPOR Europe 2023

The IGES Group will once again be present at the European conference of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). The focus will be on the new, centralized HTA procedure, EU-HTA. As part of the scientific program, IGES experts will present current analyses on orphan drugs. ISPOR Europe 2023 will take place from November 12 to 15 in Copenhagen.

Berlin, 07. November 2023 (IGES Institut) - The particular focus on the EU HTA procedure is primarily due to the existing time pressure: the first medicinal products have to undergo this EU-wide clinical evaluation procedure in less than 15 months. The procedure itself also takes place under great time pressure - with very tight deadlines and largely parallel to the approval process.

As stakeholders, the two IGES companies IGES Institut and Basel-based HealthEcon AG have contributed to the public consultations on the development of guidelines and guidance documents as part of the EUnetHTA21 activities. Participating experts will be present at ISPOR.

In the area of drug market analyses, IGES experts will present studies on the benefit assessment of orphan drugs in Germany. Among other things, they will show which factors influence the therapy costs of orphan drugs when they undergo a benefit assessment procedure again due to exceeding a sales threshold in Germany.

With its IGES LifeScience division, the IGES Group offers a wide range of research and consulting services for global developers and manufacturers of pharmaceuticals, medical devices and digital health applications. The services support all phases of the product life cycle management of new developments. They are geared towards the most important European healthcare markets.

ISPOR is the world's leading organization for health economics and outcomes research (HEOR). The congress, which takes place in Copenhagen from November 12 to 15, is one of the organization's largest annual events. The IGES Group has been contributing to the ISPOR program for many years.

IGES at ISPOR: HTA, Market Access and Strategy in Europe, EU-HTA Stakeholder.

Meet our Experts at
Booth C4-117
Floor Plan

12-15 November 2023

Bella Center
Center Blvd. 5, 2300
Copenhagen, Denmakr

Panel at BIO-EUROPE: Start early, seek advice, talk to the HTA Agencies
EU-HTA will start in time in 69 days. Fundamental implementing acts adopted – preparations under time pressure but will finish in time.
IGES Pharma at BIO Japan 2024
IGES Pharma is taking part in the BIO Japan 2024 convention, the second largest industry event of its kind for the biopharmaceutical sector. The focus is on dialogue with innovative Asian biopharmaceutical companies on market access and reimbursement in Europe.
Santoke Naal from IGES at the BIO 2024 International Convention: "It is important to engage much earlier with the HTA-Agencies than before.”
The panel “Europe's Policy Environment and the Impact on the Biotech Sector” analyzed the proposed revisions to the General Pharmaceutical Legislation (GPL) , including changes to regulatory data protection.
Expert discussion with IGES: Focus on transatlantic cooperation in the biotech sector
The world's largest biotech congress of its kind, the BIO International Convention, has a strong European focus this year. With the participation of the IGES Group, it brings together major European pharmaceutical and biotech stakeholders to discuss the latest changes in EU legislation and their consequences for the transatlantic pharmaceutical market. The congress will be held in San Diego, California, from 3 to 6 June. More than 20,000 visitors are expected to attend.
IGES Group with HTA experts at BIO-Europe Spring 2024
The IGES Group is once again taking part in BIO-Europe Spring, one of the largest trade fairs of its kind for the life sciences sector in Europe. The main focus will be on the exchange of information on the European Health Technology Assessment (HTA) procedure, EU-HTA.
Current documents on the EU-HTA process and opportunity to provide feedback
On March 5, 2024 the draft implementing regulation was published for public consultation on the “have your say” homepage of the EU – and is open for feedback for four weeks until 02 April 2024.
12 January 2025 - The Countdown runs
Pharmaceuticals and medical devices - the countdown runs! January 12, 2025, the era of national product assessments ends and the application of the EU HTA Regulation begins.
IGES Life Science at the health economics conference ISPOR Europe 2023
The IGES Group will once again be present at the European conference of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). The focus will be on the new, centralized HTA procedure, EU-HTA. As part of the scientific program, IGES experts will present current analyses on orphan drugs. ISPOR Europe 2023 will take place from November 12 to 15 in Copenhagen.
EU HTA harmonisation under time pressure: discussion at the biotech congress "BIO Europe 2023"
The time pressure due to EU HTA harmonisation is growing. In less than 15 months, the first medicinal products must undergo a central, EU-wide clinical evaluation procedure. The procedure itself is also taking place under high time pressure - with very tight deadlines and largely parallel to the marketing authorisation. What companies should urgently do now to successfully bring their new developments through the procedure is the topic of an IGES expert event at BIO Europe 2023 on 07 November in Munich.
IGES sets up a new subsidiary in France – IGES France Pharma Consulting
Continuation of its European growth course – Expansion of the services for pharmaceutical companies in Europe
IGES acquires majority stake in Synergus RWE – a European Medtech market access specialist
Continuation of its European growth course – Expansion of services for manufacturers of medical devices - Integration of the use of Scandinavian medical registries

Bringing Innovations to European Patients

IGES Life Science at the health economics conference ISPOR Europe 2023